Sex-Dependent Shared and Non-Shared Genetic Architecture Across Mood and Psychotic Disorders
Abstract
BACKGROUND Sex differences in the incidence and/or presentation of schizophrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (BIP) are pervasive. Previous evidence for shared genetic risk and sex differences in brain abnormalities across these disorders suggest possible shared sex-dependent genetic risk.
METHODS We conducted the largest to date genome-wide genotype–by–sex (GxS) interaction analysis of risk for these disorders, using data from 85,735 cases (33,403 SCZ, 19,924 BIP, 32,408 MDD) and 109,946 controls from the Psychiatric Genomics Consortium (PGC) and iPSYCH.
RESULTS Across disorders, genome-wide significant SNP-by-sex interaction was detected for a locus encompassing NKAIN2 gene (rs117780815; p=3.2×10−8), that interacts with sodium/potassium-transporting ATPase enzymes important for neuronal excitability. Three additional loci showed evidence (p<1×10−6) for cross-disorder GxS interaction (rs7302529, p=1.6×10−7; rs73033497, p=8.8×10−7; rs7914279, p=6.4×10−7) with various potential functions. Gene-based analyses identified GxS interaction across disorders (p=8.97×10−7) with transcriptional inhibitor SLTM. Most significant in SCZ was a locus in the MOCOS gene (rs11665282; p=1.5×10−7), implicating vascular endothelial cells. Secondary analysis of the SCZ PGC dataset detected a noteworthy interaction (rs13265509; p=1.1×10−7) in a locus containing IDO2, a kynurenine pathway enzyme with an immunoregulatory function previously implicated in SCZ, BIP, and MDD. Pathway enrichment analysis detected significant GxS of genes regulating vascular endothelial growth factor (VEGF) receptor signaling in MDD (pFDR<0.05).
CONCLUSIONS In the largest genome-wide GxS analysis of mood and psychotic disorders to date, there was substantial genetic overlap between the sexes. However, significant sexdependent effects were enriched for genes related to neuronal development, immune and vascular functions across and within SCZ, BIP, and MDD at the variant, gene, and pathway enrichment levels.
Competing Interest Statement
All authors declare that they have no conflicts of interest. JG is on the scientific advisory board for and has equity in Cala Health; and TLP is an employee of Concert Pharmaceuticals. However, these affiliations are unrelated to this study. JWS is an unpaid member of the Bipolar/Depression Research Community Advisory Panel of 23andMe.
Footnotes
↵14 See Acknowledgements for a full membership list and Supplemental Material for member affiliations
Subject Area
- Biochemistry (11753)
- Bioengineering (8752)
- Bioinformatics (29201)
- Biophysics (14974)
- Cancer Biology (12100)
- Cell Biology (17413)
- Clinical Trials (138)
- Developmental Biology (9422)
- Ecology (14182)
- Epidemiology (2067)
- Evolutionary Biology (18309)
- Genetics (12245)
- Genomics (16804)
- Immunology (11869)
- Microbiology (28098)
- Molecular Biology (11596)
- Neuroscience (60975)
- Paleontology (451)
- Pathology (1871)
- Pharmacology and Toxicology (3238)
- Physiology (4959)
- Plant Biology (10427)
- Synthetic Biology (2886)
- Systems Biology (7340)
- Zoology (1651)